FGF-18 Activators
FGF-18 activators represent a diverse group of chemicals that intricately modulate the activity of Fibroblast Growth Factor 18 (FGF-18), a crucial player in various cellular processes. LY294002 and Wortmannin, for instance, indirectly activate FGF-18 by inhibiting phosphoinositide 3-kinase (PI3K). Inhibition of PI3K disrupts downstream signaling, leading to increased FGF-18 activity. This PI3K-dependent modulation connects these chemicals to the regulation of FGF-18-associated cellular processes, emphasizing the significance of PI3K signaling in FGF-18 activation. U0126 and PD98059 act as indirect activators by inhibiting MEK1/2, components of the MAPK/ERK pathway. Inhibition of MEK1/2 disrupts downstream signaling, resulting in increased FGF-18 activity. This MAPK-dependent modulation establishes these chemicals as regulators of FGF-18-associated cellular processes, highlighting the role of MAPK/ERK signaling in FGF-18 activation. Furthermore, SB-203580 and SP600125 indirectly activate FGF-18 by inhibiting p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK), respectively. Inhibition of these kinases relieves their suppressive effect on FGF-18, leading to increased FGF-18 activity. This p38 MAPK and JNK-dependent modulation connects these chemicals to the regulation of FGF-18-associated cellular processes, underscoring the intricate involvement of these pathways in FGF-18 activation.
Rapamycin indirectly activates FGF-18 by inhibiting the mechanistic target of rapamycin (mTOR) signaling pathway. Inhibition of mTOR enhances FGF-18 activity, linking mTOR signaling to the regulation of FGF-18-associated cellular processes. This mTOR-dependent modulation underscores the involvement of mTOR signaling in FGF-18 activation and its impact on cellular functions. Wortmannin indirectly activates FGF-18 by inhibiting phosphoinositide 3-kinase (PI3K). Inhibition of PI3K disrupts downstream signaling, resulting in increased FGF-18 activity. This PI3K-dependent modulation connects Wortmannin to the regulation of FGF-18-associated cellular processes, highlighting the role of PI3K signaling in FGF-18 activation. These activators collectively showcase the intricate regulatory network governing FGF-18 activity, emphasizing the diverse signaling pathways that converge to modulate FGF-18-associated cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 indirectly activates FGF-18 by inhibiting phosphoinositide 3-kinase (PI3K). Inhibition of PI3K by LY294002 disrupts downstream signaling, resulting in enhanced FGF-18 activity. This PI3K-dependent modulation connects LY294002 to the regulation of FGF-18-associated cellular processes, emphasizing the role of PI3K signaling in FGF-18 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580 indirectly activates FGF-18 by inhibiting p38 mitogen-activated protein kinase (MAPK). Inhibition of p38 MAPK by SB-203580 relieves its suppressive effect on FGF-18, leading to increased FGF-18 activity. This p38 MAPK-dependent modulation connects SB-203580 to the regulation of FGF-18-associated cellular processes, highlighting the role of p38 MAPK signaling in FGF-18 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 indirectly activates FGF-18 by inhibiting c-Jun N-terminal kinase (JNK), a component of the MAPK signaling pathway. Inhibition of JNK by SP600125 disrupts downstream signaling, resulting in increased FGF-18 activity. This JNK-dependent modulation establishes SP600125 as a regulator of FGF-18-associated cellular processes, emphasizing the role of JNK signaling in FGF-18 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin indirectly activates FGF-18 by inhibiting phosphoinositide 3-kinase (PI3K). Inhibition of PI3K by Wortmannin disrupts downstream signaling, resulting in increased FGF-18 activity. This PI3K-dependent modulation connects Wortmannin to the regulation of FGF-18-associated cellular processes, highlighting the role of PI3K signaling in FGF-18 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 indirectly activates FGF-18 by inhibiting MEK1/2, components of the MAPK/ERK pathway. Inhibition of MEK1/2 by PD98059 disrupts downstream signaling, leading to increased FGF-18 activity. This MAPK-dependent modulation establishes PD98059 as a regulator of FGF-18-associated cellular processes, emphasizing the significance of MAPK/ERK signaling in FGF-18 activation. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB-216763 indirectly activates FGF-18 by inhibiting glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 by SB-216763 enhances FGF-18 activity, linking GSK-3 signaling to the regulation of FGF-18-associated cellular processes. This GSK-3-dependent modulation underscores the involvement of GSK-3 signaling in FGF-18 activation and its impact on cellular functions. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 indirectly activates FGF-18 by inhibiting Src kinase, a component of the Src family kinases. Inhibition of Src kinase by SU6656 disrupts downstream signaling, resulting in increased FGF-18 activity. This Src kinase-dependent modulation connects SU6656 to the regulation of FGF-18-associated cellular processes, emphasizing the role of Src kinase signaling in FGF-18 activation. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI (CHIR99021) indirectly activates FGF-18 by inhibiting glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 by CHIR99021 enhances FGF-18 activity, linking GSK-3 signaling to the regulation of FGF-18-associated cellular processes. This GSK-3-dependent modulation underscores the involvement of GSK-3 signaling in FGF-18 activation and its impact on cellular functions. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 indirectly activates FGF-18 by inhibiting transforming growth factor-beta (TGF-β) type I receptor. Inhibition of TGF-β receptor by SB-431542 enhances FGF-18 activity, linking TGF-β signaling to the regulation of FGF-18-associated cellular processes. This TGF-β receptor-dependent modulation underscores the involvement of TGF-β signaling in FGF-18 activation and its impact on cellular functions. | ||||||